Prognostic Role of 18F-FDG PET/CT in the Postoperative Evaluation of Differentiated Thyroid Cancer Patients(406 views) Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M
Keywords: Differentiated Thyroid Cancer, Fdg Pet Ct, Progression-Free Survival, Fluorodeoxyglucose F 18, Iodine 131, Levothyroxine, Thyroglobulin, Adult, Article, Cancer Prognosis, Cancer Recurrence, Cancer Staging, Cancer Survival, Clinical Feature, Computer Assisted Emission Tomography, Computer Assisted Tomography, Controlled Study, Distant Metastasis, Female, Follow Up, Human, Lymph Node, Major Clinical Study, Middle Aged, Postoperative Period, Progression Free Survival, Whole Body Scintiscanning, Radiopharmaceutical Agent, Adenocarcinoma, Diagnostic Use, Evaluation Study, Multimodal Imaging, Positron Emission Tomography, Thyroid Neoplasms, Positron-Emission Tomography, X-Ray Computed, Adenocarcinoma Diagnostic Imaging Surgery
, Fluorodeoxyglucose F18
, Thyroid Neoplasms Diagnostic Imaging Surgery,
Affiliations: *** IBB - CNR ***
From the *Dipartimento di Medicina e Chirurgia, Universita degli Studi di Salerno, Salerno
Dipartimento di Scienze Biomediche Avanzate, Universita degli Studi di Napoli Federico II
Istituto di Biostrutture e Bioimmagini, CNR
and ║IRCSS CROB, Rionero in Vulture, Italia.
IRCSS SDNNapoli, Italy
IRCSS CROBRionero in Vulture, Italy
daggerDipartimento di Scienze Biomediche Avanzate, Universita degli Studi di Napoli Federico II
double daggerIstituto di Biostrutture e Bioimmagini, CNR
section signIRCSS SDN, Napoli
and vertical lineIRCSS CROB, Rionero in Vulture, Italia.
IRCSS SDN, Napoli, Italy
References: Davies, L., Welch, H.G., Increasing incidence of thyroid cancer in the united states, 1973-2002 (2006) JAMA, 295, pp. 2164-216
Cooper, D.S., Doherty, G.M., Haugen, B.R., Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer (2009) Thyroidology, 19, pp. 1167-1214
Goldsmith, S.J., To ablate or not to ablate: Issues and evidence involved in 131-i ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma (2011) Semin Nucl Med, 41, pp. 96-104
Wang, W., MacApinlac, H., Larson, S.M., #sup#18#/sup#f]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (#sup#131#/sup#)i whole body scans and elevated serum thyroglobulin levels (1999) J Clin Endocrinol Metab, 84, pp. 2291-2302
Wang, W., Larson, S.M., Fazzari, M., Prognostic value of [#sup#18#/sup#f]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer (2000) J Clin Endocrinol Metab, 85, pp. 1107-1113
Helal, B.O., Merlet, P., Toubert, M.E., Clinical impact of (#sup#18#/sup#)f-fdg pet in thyroid carcinoma patients with elevated thyroglobulin levels and negative (#sup#131#/sup#)i scanning results after therapy (2001) J Nucl Med, 42, pp. 1464-1469
Schluter, B., Bohuslavizki, K.H., Beyer, W., Impactof fdg petonpatients with differentiated thyroid cancer who present with elevated thyroglobulin and negative #sup#131#/sup#i scan (2001) J Nucl Med, 42, pp. 71-76
Van Tol, K.M., Jager, P.L., Piers, D.A., Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation (2002) Thyroid, 12, pp. 381-387
Frilling, A., Tecklenborg, K., Gorges, R., Preoperative value of #sup#18#/sup#f fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma (2001) Ann Surg, 234, pp. 804-811
Giammarile, F., Hafdi, Z., Bournaud, C., Is [#sup#18#/sup#f]-2-fluoro-2-deoxy-d-glucose (fdg) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake (2003) Eur J Endocrinol, 149, pp. 293-300
Goshen, E., Cohen, O., Rotenberg, G., The clinical impact of #sup#18#/sup#f-fdg-pet in patients with recurrent well-differentiated thyroid carcinoma (2003) Nucl Med Commun, 24, pp. 959-961
Nahas, Z., Goldenberg, D., Fakhry, C., The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma (2005) Laryngoscope, 115, pp. 237-243
Robbins, R.J., Wan, Q., Grewal, R.K., Real-Time prognosis for metastatic thyroid carcinoma based on fdg-pet scanning (2006) J Clin Endocrinol Metab, 91, pp. 498-505
Palmedo, H., Bucerius, J., Joe, A., Integrated pet/ct in differentiated thyroid cancer: Diagnostic accuracy and impact on patient management (2006) J Nucl Med, 47, pp. 616-624
Shammas, A., Degirmenci, B., Mountz, J.M., #sup#18#/sup#f-fdg pet/ctin patients with suspected recurrent or metastatic well-differentiated thyroid cancer (2007) J Nucl Med, 48, pp. 221-226
Mirallie, E., Guillan, T., Bridji, B., Therapeutic impact of #sup#18#/sup#fdg-pet/ct in the management of iodine-negative recurrence of differentiated thyroid carcinoma (2007) Surgery, 142, pp. 952-958
Leboulleux, S., Schroeder, P.R., Schlumberger, M., The roleofpet in follow-up of patients treated for differentiated epithelial thyroid cancers (2007) Nat Clin Pract Endocrinol Metab, 3, pp. 112-121
Freudenberg, L.S., Frilling, A., Kühl, H., Dual-modality fdg pet/ctinfollow-up of patients with recurrent iodine-negative differentiated thyroid cancer (2007) Eur Radiol, 17, pp. 3139-3147
Iagaru, A., Kalinyak, J.E., McDougall, I.R., F-18 fdg pet/ctin the management of thyroid cancer (2007) Clin Nucl Med, 32, pp. 690-695
Menzel, C., Zaplatnikov, K., Diehl, M., The influence of thyroglobulin on functional imaging in differentiated thyroid cancer (2004) Nucl Med Commun, 25, pp. 239-243
Bertagna, F., Bosio, G., Biasiotto, G., F-18 fdg-pet/ctevaluation of patients with differentiated thyroid cancer with negative i-131 total body scan and high thyroglobulin level (2009) Clin Nucl Med, 34, pp. 756-761
Abraham, T., Schoder, H., Thyroid cancer-indications and opportunities for positron emission tomography/computed tomography imaging (2011) Semin Nucl Med, 41, pp. 121-138
Salvatore, B., Paone, G., Klain, M., Fluorodeoxyglucose positron emission tomography/computed tomography in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131-i ablation (2007) Q J Nucl Med Mol Imaging, 51, pp. 1-7
Iwano, S., Kato, K., Ito, S., Fdg-pet performed concurrently with initial i-131 ablation for differentiated thyroid cancer (2012) Ann Nucl Med, 26, pp. 207-213
Rosenbaum-Krumme, S.J., Gorges, R., Bockisch, A., #sup#18#/sup#f-fdg pet/ct changes therapy management in high-risk dtc after first radioiodine therapy (2012) Eur J Nucl Med Mol Imaging, 39, pp. 1373-1380
Lee, J.W., Lee, S.M., Lee, D.H., Clinical utility of #sup#18#/sup#f-fdg pet/ct concurrent with therapy in intermediate-To-high-risk patients with differentiated thyroid cancer: Dual-center experience with 286 patients (2013) J Nucl Med, 54, pp. 1230-1236
Pace, L., Nicolai, E., Klain, M., Diagnostic value of fdg pet/ct imaging (2009) Q J Nucl Med Mol Imaging, 53, pp. 503-512
Jeong, H.S., Baek, C.H., Son, Y.I., Integrated #sup#18#/sup#f-fdg pet/ct for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: Comparison with ultrasound and contrast-enhanced ct (2006) Clin Endocrinol (Oxf, 65, pp. 402-407
Al-Zahrani, A.S., Abouzied, M.E.M., Salam, S.A., The role of f-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer (2008) Eur J Endocrinol, 158, pp. 683-689
Matsuzu, K., Segade, F., Matsuzu, U., Differential expression of glucose transporters in normal and pathologic thyroid tissue (2004) Thyroid, 14, pp. 806-812
Mian, C., Barollo, S., Pennelli, G., Molecular characteristics in papillary thyroid cancers (ptcs) with no #sup#131#/sup#i uptake (2008) Clin Endocrinol (Oxf, 68, pp. 108-116
Ricarte-Filho, J.C., Ryder, M., Chitale, D.A., Mutational profile of advanced primary and metastatic radioactive iodine refractory thyroid cancers reveals distinct pathogenetic roles for braf pik3ca and akt1 (2009) Cancer Res, 69, pp. 4885-4893
Pacini, F., Schlumberger, M., Dralle, H., European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium (2006) Eur J Endocrinol, 154, pp. 787-803
Prognostic Role of 18F-FDG PET/CT in the Postoperative Evaluation of Differentiated Thyroid Cancer Patients